Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study.

Autor: Yan XQ; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing., Ye MJ; Department of Urology, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha., Zou Q; Department of Urology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & Affiliated Cancer Hospital of Nanjing Medical University, Nanjing., Chen P; Department of Urology, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi., He ZS; Department of Urology, First Hospital of Peking University, Beijing., Wu B; Department of Urology, Shengjing Hospital of China Medical University, Shenyang., He DL; Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an., He CH; Department of Urology, Cancer Hospital of Henan Province, Zhengzhou., Xue XY; Department of Urology, The First Affiliated Hospital, Fujian Medical University, Fuzhou., Ji ZG; Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing., Chen H; Department of Urology, Harbin Medical University Cancer Hospital, Harbin., Zhang S; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu., Liu YP; Department of Oncology, The First Hospital of China Medical University, Shenyang., Zhang XD; Department of Urology, Beijing Chaoyang Hospital, Capital Medical University, Beijing., Fu C; Department of Urology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang., Xu DF; Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai., Qiu MX; Department of Urology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu., Lv JJ; Department of Urology, Provincial Hospital Affiliated to Shandong First Medical University, Jinan., Huang J; Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou., Ren XB; Department of Immunology and Biotherapy, Cancer Institute & Hospital, Tianjin Medical University, Tianjin., Cheng Y; Department of Medical Thoracic Oncology, Jilin Provincial Cancer Hospital, Changchun., Qin WJ; Department of Urology, Xijing Hospital of Air Force Military Medical University, Xi'an., Zhang X; Department of Urology, The Third Medical Center, Chinese PLA General Hospital, Beijing., Zhou FJ; Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou., Ma LL; Department of Urology, Peking University Third Hospital, Beijing., Guo JM; Department of Urology, Zhongshan Hospital, Fudan University, Shanghai., Ding DG; Department of Urology, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Zhengzhou., Wei SZ; Department of Urology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan., He Y; Department of Urology, The Affiliated Hospital of Jiaxing University, Jiaxing., Guo HQ; Department of Urology, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing., Shi BK; Department of Urology, Qilu Hospital of Shandong University, Jinan., Liu L; Department of Urology, Qilu Hospital of Shandong University, Jinan., Liu F; Department of Urology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou., Hu ZQ; Department of Urology, Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, Wuhan., Jin XM; Department of Oncology, General Hospital of Ningxia Medical University, Yinchuan., Yang L; Department of Urology, The Second Hospital of Lanzhou University, Lanzhou., Zhu SX; Department of Urology, Fujian Medical University Union Hospital, Fuzhou., Liu JH; Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Kunming., Huang YH; Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou., Xu T; Department of Urology, Peking University People's Hospital, Beijing., Liu B; Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou., Sun T; Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang., Wang ZJ; Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing., Jiang HW; Department of Urology, Huashan Hospital, Fudan University, Shanghai., Yu DX; Department of Urology, The Second Affiliated Hospital of Anhui Medical University, Hefei., Zhou AP; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing., Jiang J; Department of Urology, The PLA General Hospital Army Characteristic Medical Center, Chongqing., Luan GD; Shanghai Junshi Biosciences Co., Ltd., Shanghai., Jin CL; Shanghai Junshi Biosciences Co., Ltd., Shanghai., Xu J; Shanghai Junshi Biosciences Co., Ltd., Shanghai., Hu JX; Shanghai Junshi Biosciences Co., Ltd., Shanghai., Huang YR; Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China., Guo J; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing., Zhai W; Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address: jacky_zw2002@hotmail.com., Sheng XN; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing. Electronic address: doctor_sheng@126.com.

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2024 Feb; Vol. 35 (2), pp. 190-199. Date of Electronic Publication: 2023 Oct 21.

Multi-networks connectivity at baseline predicts the clinical efficacy of left angular gyrus-navigated rTMS in the spectrum of Alzheimer's disease: A sham-controlled study.

Autor: Chen HF; Department of Neurology, Drum Tower Hospital, Medical School and The State Key Laboratory of Pharmaceutical Biotechnology, Institute of Brain Science, Nanjing University, Nanjing, China.; Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China.; Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing, China.; Jiangsu Province Stroke Center for Diagnosis and Therapy, Nanjing, China.; Nanjing Neuropsychiatry Clinic Medical Center, Nanjing, China., Sheng XN; Department of Neurology, Drum Tower Hospital, Medical School and The State Key Laboratory of Pharmaceutical Biotechnology, Institute of Brain Science, Nanjing University, Nanjing, China.; Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing, China.; Jiangsu Province Stroke Center for Diagnosis and Therapy, Nanjing, China.; Nanjing Neuropsychiatry Clinic Medical Center, Nanjing, China., Yang ZY; Department of Neurology, Drum Tower Hospital, Medical School and The State Key Laboratory of Pharmaceutical Biotechnology, Institute of Brain Science, Nanjing University, Nanjing, China.; Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing, China.; Jiangsu Province Stroke Center for Diagnosis and Therapy, Nanjing, China.; Nanjing Neuropsychiatry Clinic Medical Center, Nanjing, China., Shao PF; Department of Neurology, Drum Tower Hospital, Medical School and The State Key Laboratory of Pharmaceutical Biotechnology, Institute of Brain Science, Nanjing University, Nanjing, China.; Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing, China.; Jiangsu Province Stroke Center for Diagnosis and Therapy, Nanjing, China.; Nanjing Neuropsychiatry Clinic Medical Center, Nanjing, China., Xu HH; Department of Neurology, Drum Tower Hospital, Medical School and The State Key Laboratory of Pharmaceutical Biotechnology, Institute of Brain Science, Nanjing University, Nanjing, China.; Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing, China.; Jiangsu Province Stroke Center for Diagnosis and Therapy, Nanjing, China.; Nanjing Neuropsychiatry Clinic Medical Center, Nanjing, China., Qin RM; Department of Neurology, Drum Tower Hospital, Medical School and The State Key Laboratory of Pharmaceutical Biotechnology, Institute of Brain Science, Nanjing University, Nanjing, China.; Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing, China.; Jiangsu Province Stroke Center for Diagnosis and Therapy, Nanjing, China.; Nanjing Neuropsychiatry Clinic Medical Center, Nanjing, China., Zhao H; Department of Neurology, Drum Tower Hospital, Medical School and The State Key Laboratory of Pharmaceutical Biotechnology, Institute of Brain Science, Nanjing University, Nanjing, China.; Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing, China.; Jiangsu Province Stroke Center for Diagnosis and Therapy, Nanjing, China.; Nanjing Neuropsychiatry Clinic Medical Center, Nanjing, China., Bai F; Department of Neurology, Drum Tower Hospital, Medical School and The State Key Laboratory of Pharmaceutical Biotechnology, Institute of Brain Science, Nanjing University, Nanjing, China.; Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China.; Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing, China.; Jiangsu Province Stroke Center for Diagnosis and Therapy, Nanjing, China.; Nanjing Neuropsychiatry Clinic Medical Center, Nanjing, China.; Geriatric Medicine Center, Affiliated Taikang Xianlin Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China.

Publikováno v: CNS neuroscience & therapeutics [CNS Neurosci Ther] 2023 Aug; Vol. 29 (8), pp. 2267-2280. Date of Electronic Publication: 2023 Mar 21.

[Preliminary effects of toripalimab combined with axitinib in the treatment of advanced renal cell carcinoma].

Autor: Zhou L; Department of Genitourinary Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China., Xu HY; Department of Genitourinary Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China., Yan XQ; Department of Genitourinary Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China., Li SM; Department of Genitourinary Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China., Chi ZH; Department of Melanoma and Sarcoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China., Si L; Department of Melanoma and Sarcoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China., Cui ZL; Department of Melanoma and Sarcoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China., Li J; Department of Genitourinary Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China., Wu XW; Department of Genitourinary Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China., Guo J; Department of Genitourinary Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China., Sheng XN; Department of Genitourinary Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China.

Publikováno v: Zhonghua yi xue za zhi [Zhonghua Yi Xue Za Zhi] 2022 Jan 11; Vol. 102 (2), pp. 136-140.

The natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients.

Autor: Lian B; Department of Renal Cancer & Melanoma, Peking University Cancer Hospital & Institute, Beijing, China., Cui CL; Department of Renal Cancer & Melanoma, Peking University Cancer Hospital & Institute, Beijing, China., Zhou L; Department of Renal Cancer & Melanoma, Peking University Cancer Hospital & Institute, Beijing, China., Song X; Department of Melanoma, Yunnan Cancer Hospital, Kunming, China., Zhang XS; Department of Melanoma, SUN YAT-SEN University Cancer Center, Guangzhou, China., Wu D; Department of Melanoma, The First Hospital of Jilin University, Changchun, China., Si L; Department of Renal Cancer & Melanoma, Peking University Cancer Hospital & Institute, Beijing, China., Chi ZH; Department of Renal Cancer & Melanoma, Peking University Cancer Hospital & Institute, Beijing, China., Sheng XN; Department of Renal Cancer & Melanoma, Peking University Cancer Hospital & Institute, Beijing, China., Mao LL; Department of Renal Cancer & Melanoma, Peking University Cancer Hospital & Institute, Beijing, China., Wang X; Department of Renal Cancer & Melanoma, Peking University Cancer Hospital & Institute, Beijing, China., Tang BX; Department of Renal Cancer & Melanoma, Peking University Cancer Hospital & Institute, Beijing, China., Yan XQ; Department of Renal Cancer & Melanoma, Peking University Cancer Hospital & Institute, Beijing, China., Kong Y; Department of Renal Cancer & Melanoma, Peking University Cancer Hospital & Institute, Beijing, China., Dai J; Department of Renal Cancer & Melanoma, Peking University Cancer Hospital & Institute, Beijing, China., Li SM; Department of Renal Cancer & Melanoma, Peking University Cancer Hospital & Institute, Beijing, China., Bai X; Department of Renal Cancer & Melanoma, Peking University Cancer Hospital & Institute, Beijing, China., Zheng N; Clinical Pharmacology Research Centre, Peking University Cancer Hospital & Institute, Beijing, China., Balch CM; Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Guo J; Department of Renal Cancer & Melanoma, Peking University Cancer Hospital & Institute, Beijing, China.

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2017 Apr 01; Vol. 28 (4), pp. 868-873.